EHA 2019 | Venetoclax and obinutuzumab for CLL
Brian Koffman, MDCM, DCFP, DABFM, MS Ed, Saint Jude Medical Center, Fullerton, CA, discusses the recent FDA approval of venetoclax in combination with obinutuzumab for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) and how this may impact patients in the clinical setting. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
Transcript (edited for clarity)
So the recent FDA approval of venetoclax and obinutuzumab frontline in CLL is really a tremendous option from a patient’s perspective because for the first time we have an extremely efficacious and quite safe
So the recent FDA approval of venetoclax and obinutuzumab frontline in CLL is really a tremendous option from a patient’s perspective because for the first time we have an extremely efficacious and quite safe treatment to use that is non-chemotherapy based, and is limited duration, and has very strong outcomes with a significant percentage of patients reaching no detectable disease in their bone marrow and blood at two years. And with the side-effect profile it can be managed both in the community, and at clinical trials.
Read more...
